DNA mismatch-specific targeting and hypersensitivity of mismatch-repair-deficient cells to bulky rhodium(III) intercalators by Hart, Jonathan R. et al.
bulky rhodium(III) intercalators
DNA mismatch-specific targeting and hypersensitivity of mismatch-repair-deficient cells to
Jonathan R. Hart, Oleg Glebov, Russell J. Ernst, Ilan R. Kirsch, and Jacqueline K. Barton 
doi:10.1073/pnas.0607576103 
 published online Oct 9, 2006; PNAS
 This information is current as of October 2006.
 www.pnas.org#otherarticles
This article has been cited by other articles: 
 E-mail Alerts
. click hereat the top right corner of the article or
Receive free email alerts when new articles cite this article - sign up in the box
 Rights & Permissions
 www.pnas.org/misc/rightperm.shtml
To reproduce this article in part (figures, tables) or in entirety, see: 
 Reprints
 www.pnas.org/misc/reprints.shtml
To order reprints, see: 
 Notes:
DNA mismatch-specific targeting and hypersensitivity
of mismatch-repair-deficient cells to bulky
rhodium(III) intercalators
Jonathan R. Hart*, Oleg Glebov†, Russell J. Ernst*, Ilan R. Kirsch†‡, and Jacqueline K. Barton*§
*Division of Chemistry and Chemical Engineering, California Institute of Technology Pasadena, CA 91125; and †Genetics Branch, Center for Cancer Research,
National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889
Contributed by Jacqueline K. Barton, August 31, 2006
Mismatch repair (MMR) is critical to maintaining the integrity of the
genome, and deficiencies in MMR are correlated with cancerous
transformations. Bulky rhodium intercalators target DNA base
mismatches with high specificity. Here we describe the application
of bulky rhodium intercalators to inhibit cellular proliferation
differentially in MMR-deficient cells compared with cells that are
MMR-proficient. Preferential inhibition by the rhodium complexes
associated with MMR deficiency is seen both in a human colon
cancer cell line and in normal mouse fibroblast cells; the inhibition
of cellular proliferation depends strictly on the MMR deficiency of
the cell. Furthermore, our assay of cellular proliferation is found to
correlate with DNA mismatch targeting by the bulky metal-
lointercalators. It is the -isomer that is active both in targeting
base mismatches and in inhibiting DNA synthesis. Additionally, the
rhodium intercalators promote strand cleavage at the mismatch
site with photoactivation, and we observe that the cellular re-
sponse is enhanced with photoactivation. Targeting DNA mis-
matches may therefore provide a cell-selective strategy for che-
motherapeutic design.
DNA base mismatch  metallointercalator
The DNA mismatch repair (MMR) machinery is responsiblefor the recognition and repair of mispaired or damagedDNA
bases (1, 2). With a deficiency in MMR, cellular mutation rates
are enhanced (3, 4), and individuals who have inherited a
defective copy of MMR genes are at risk of developing cancers,
in particular, hereditary nonpolyposis colon cancer (5, 6). Also
noteworthy, 18% of solid tumors and 10% of leukemias tested
are deficient inMMR (7–9). AlthoughMMRdeficiencies are not
a constant in cancer, they can greatly accelerate the rate at which
mismatches and, thus, mutations accumulate.
Deficiencies in MMR have been particularly difficult to target
therapeutically, because, in addition to being a predisposing
factor for the formation of tumors,MMRdeficiency is associated
with a tolerance to many common chemotherapeutics, including
alkylating agents, platinum compounds, topoisomerase inhibi-
tors, and metabolic analogues (10). MMR-deficient cell lines
have, however, recently been shown to be hypersensitive to a
small family of drugs that target DNA (11–13). It has also been
suggested that some recurrent tumors that are drug-resistant
obtain this resistance through MMR deficiency (14).
We have developed bulky rhodium intercalators (Fig. 1) that
bind single base mismatches in DNA selectively and irrespective
of sequence context (15–18). These compounds bind the mis-
match by intercalation and, upon photoexcitation, promote
strand breaks at the mismatched site. [Bis(2,2-bipyridine)
(chrysene-5,6-quinone-diimine)Rh(III)] (Rhchrysi) binds mis-
matches with moderate affinity and high specificity. The site-
specificity depends on the thermodynamic instability associated
with a base pair mismatch; the bulky intercalator cannot stack
easily within well matched DNA but can more easily insert
neighboring a destabilized mismatched site. The high specificity
of Rhchrysi is well demonstrated in its ability to cleave a single
mismatched site in a 2,700-bp duplex (16). This specificity has
been used advantageously in a site-specific assay for single-
nucleotide polymorphisms in pooled genomic DNA (19). Our
second generation complex [bis(2,2-bipyridine)(benzo[a]
phenazine-5,6-quinonediimine)Rh(III)] (Rhphzi) utilizes het-
erocyclic nitrogen atoms within the bulky intercalating ligand to
boost the affinity of the complex for mismatched sites (18).
Rhphzi is capable of binding mismatched sites with 100 nM
affinity and with specificity similar to Rhchrysi.
Importantly, both of these rhodium complexes recently have
been applied in probing whether MMR-deficient cells accu-
mulate mismatches (18). In photocleavage assays of genomic
DNA from a series of cell lines, some proficient in MMR and
others wholly or partially deficient in repair, a clear correlation
between photocleavage by Rhchrysi and Rhphzi and MMR
deficiency was evident.
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Fig. 1. Structures of -Rhchrysi (Upper Left), -Rhchrysi (Upper Right), and
-Rhphzi (Lower).
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Here we explore the efficacy of these rhodium complexes in
inhibiting the growth of MMR-deficient versus MMR-proficient
cell lines in the presence and absence of photoactivation. The
biological effects are assessed in two cell lines, both of which are
derivatives of HCT116. These cell lines have had an extra copy of
either chromosome 2, HCT116O, or chromosome 3, HCT116N,
inserted in the cell; placing a copy of chromosome 3 within this cell
line corrects the MMR deficiency by introducing a functional copy
of the MLH1 gene with a normal promoter (20). Additionally,
mouse fibroblast cells derived from litter mates that are Msh2 or
Msh2were studied. These cells and cell lines provide a convenient
method for testing whether a particular compound will differen-
tially target MMR-deficient cells, because these cells are essentially
identical genetically, except with regard to MMR.
Results
Preferential Inhibition of Cellular Proliferation with MMR Deficiency
by the Rhodium Complexes. TheHCT116-derived cells were treated
with either Rhchrysi or Rhphzi for 96 h at various concentrations
in the absence of irradiation. As is evident for both complexes at
micromolar concentrations (Fig. 2), we see a significant inhibition
of cell proliferation. Importantly, for both complexes we also see a
preferential inhibition in theMMR-deficient strain. This selectivity
seen with the rhodium complexes for the MMR-deficient
HCT116O contrasts the action, also shown, of N-methyl, N-nitro-
nitrosoguanidine (MNNG), a common DNA-methylating agent
that is found to be more toxic to the MMR-proficient cell line,
HCT116N (20). MNNG is typical of most chemotherapeutics that
target genomic DNA.
Experiments using normal mouse fibroblasts that are deficient
for MMR, Msh2, or proficient for MMR, Msh2, were also
performed. These experiments complement those conducted
with HCT116, because these cells also are genetically identical
except for the Msh2 gene. Experiments probing these fibroblast
cells, which are not cancerous, therefore provide a rigorous test
that targets MMR deficiency. The data given in Fig. 3 show that
the MMR-defective mouse embryo fibroblasts that are Msh2
yield decreased DNA synthesis and are therefore more sensitive
to Rhphzi compared with the control littermate cells that are
Msh2. These results parallel those obtained with the HCT116
model system. These results furthermore provide strong support
for the idea that the inhibition of cell proliferation is related to
the MMR deficiency of the cell, regardless of which MMR gene
is absent.
The effect of incubation time was also investigated, and the
results are shown in Fig. 4. HCT116 cells were exposed to various
concentrations of Rhchrysi for various amounts of time, from 6 to
96 h, before testing the effects on DNA synthesis. In this series, it
is clear that themaximumeffect is obtained after 48 h of incubation.
Based on cellular uptake studies with closely related ruthenium
complexes that are fluorescent (J.K.B. and C. Puckett, unpublished
results), we expect cellular uptake to be rate-limiting; indeed, with
more hydrophobic chrysi analogues, we find differential biological
effects with much shorter incubation times.
Significantly, the results seen here with the bulky rhodium
complexes are distinctive, in contrast to common therapeutics
and MNNG. MMR-deficient cell lines are generally resistant to
the majority of alkylating drugs, platinum compounds, and
metabolic analogues, because the antiproliferative effects these
therapeutic agents have on cancerous cells are due in part to
recognition of the drug-induced genomic DNA damage by the
MMR system (10, 21). In contrast, we find with the rhodium
Fig. 2. Differential antiproliferative effect of rac-Rhchrysi, rac-Rhphzi, and
MNNG on MMR-deficient (red) and MMR-proficient (green) cells. MMR-
deficient, O, and MMR-proficient, N, cell lines derived from the HCT116 cell
line were treated with the methylating agent MNNG, Rhchrysi, or Rhphzi as
described in Materials and Methods. Complexes and MNNG were incubated
with cells for 96 h with the addition of BrdU after 72 h. Note that the
MMR-deficient population HCT116O is resistant to the action of MNNG but is
sensitive preferentially to Rhchrysi and Rhphzi.
Fig. 3. Antiproliferative effect of rac-Rhphzi on MMR-deficient, Msh2
(red), and MMR-proficient, Msh2 (green), mouse embryonic fibroblasts.
Inhibition of DNA synthesis in the MMR-deficient mouse cells parallels the
effects seen with the HCT116 cell lines.
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complexes the preferential inhibition of cellular proliferation in
cells that depends strictly on their deficiency in MMR.
Correlations Between Biological Effects and DNAMismatch Targeting.
In an effort to correlate the biological effects we observed by
using these bulky intercalators with their DNA-binding charac-
teristics, experiments also were conducted with enantiomers of
Rhchrysi. Only the -isomer of Rhchrysi binds and cleaves, with
photoactivation, a neighboring mismatched DNA site (15).
Shown in Fig. 5 is an illustration of the enantiospecific reaction
of -Rhchrysi at a single CC mismatch on a 436-mer DNA
duplex PCR product containing a single CC mismatch. As
illustrated in the capillary gel electrophoresis results, upon
photolysis of the complex bound to DNA, the bulky -isomer
cleaves the DNA neighboring the destabilized mismatch. No
cleavage is seen without metal complex (light control) or after
photolysis using the -isomer. In general, by surveying different
mismatched sites in a variety of sequence contexts, we have
found the recognition to be enantioselective; it is -Rhchrysi
that binds and cleaves mismatched DNA preferentially (17).
We therefore also compared the antiproliferative effects of
the separated isomers (Fig. 5). Consistent with DNA targeting
studies, it is -Rhchrysi that shows selective inhibition of cellular
proliferation in the MMR-deficient HCT116O cell line. At 5 M
rhodium, incubation with -Rhchrysi shows no effect on DNA
synthesis in either HCT116O or HCT116N cells, whereas the
-isomer selectively inhibits DNA synthesis in the MMR-
deficient HCT116O cells. Although these rhodium complexes
are coordinatively saturated and generally inert to substitution,
we had considered the possibility that the biological activity of
the complexes might be associated with complex decomposition
and ligand release. The finding of high enantioselectivity asso-
Fig. 4. Effect of varying drug incubation time on cell proliferation. HCT116 cells that are deficient (red) and proficient (green) in MMR were exposed to various
concentrations of rac-Rhchrysi for different incubation times as shown. Antiproliferative effects increase with longer incubation times up to 48 h.
Fig. 5. DNA cleavage and biological activities with stereoisomers and light. (A) Effect of stereoisomers on photocleavage. Shown are capillary electrophero-
grams after photolysis of 436-mer PCR products containing a single CC mismatch with 500 nM-Rhchrysi (Upper) or-Rhchrysi (Lower), as described earlier (12).
Mismatch-specific photocleavage to produce a 170-bp fragment is evident only with the -isomer. (B) Antiproliferative effects of different stereoisomers of
Rhchrysi. Shown are the effects on BrdU incorporation in HCT116O (red) and HCT116N (green) cells after 48 h of incubation without rhodium or with 5 M -
or -Rhchrysi. The selective inhibition of the MMR-deficient HCT116O cell line is seen only with the -isomer. (C) Antiproliferative effect of different
stereoisomers of Rhchrysi with irradiation. Shown are the effects of various amounts of irradiation of HCT116O cells in the absence of Rhchrysi (black), in the
presence of 5 M -Rhchrysi (red), or in the presence of 5 M -Rhchrysi (blue) after 48 h of incubation.
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ciated with the biological effect argues against complex decom-
position as being responsible for the inhibition of cellular
proliferation, given that a similar decomposition would be likely
for both isomers.
Because the complexes bind mismatched DNA only nonco-
valently in the absence of light but, with photolysis, promote
DNA strand breaks, we also explored cell proliferation assays
after exposing the cells to compound and light, conditions under
which the rhodium complex might be expected to be more
potent. We therefore irradiated cells for 10, 15, or 20 min after
a 48-h incubation with rhodium. These results also are shown in
Fig. 5. Here it should be noted that longer periods of irradiation
even without metal complex lead to some inhibitory effects in
both MMR deficient and proficient cell lines; evaporation of the
medium is also somewhat of a problem. Nonetheless, light
activation over short periods does indeed lead to greater inhi-
bition of cell proliferation and only for -Rhchrysi in the MMR
deficient HCT116O cells. Again, parallel experiments with
-Rhchrysi provide a useful control. Under the conditions used,
light activation only appears to enhance the inhibition of DNA
synthesis by -Rhchrysi and only in the MMR deficient
HCT116O cells. These data are consistent with DNA serving as
target for the rhodium complex inside the cell. Certainly these
results demonstrate a clear correlation between mismatch tar-
geting by rhodium photocleavage and biological potency in a
cell-selective manner.
Discussion
The results reported here establish that the bulky rhodium inter-
calators we have designed serve as inhibitors of cellular prolifera-
tion and, significantly, that the complexes do so with cell selectivity.
Biological effects are seen preferentially in MMR-deficient cells.
These results do not establish DNAmismatch targeting as the basis
for the cell selectivity. However, these data are consistent with
mismatched DNA being the target of these complexes and, hence,
the basis of the preferential reaction inMMR-deficient cell lines, in
which mismatches are more abundant.
It is noteworthy that in the absence of light the complexes bind
DNA mismatches noncovalently, albeit with high affinity and
specificity. Because a covalent adduct is not formed and, in the
absence of light, no DNA damage is directly generated, any
biological effect would be expected to be more modest; irradi-
ation, which does cause DNA strand breaks, should enhance the
effect, as we observe. Likely, then, without light the metal-
mismatch complex provides a secondary signal for protein
binding or activation. It should also be noted that light activation
of the metal complex generates only a short-lived ligand radical;
thus, intimate association of the rhodium complex with its target
is needed for a light-dependent reaction (22).
Significantly, the biological effects we observed in MMR-
deficient cells also are enantiospecific, just as binding of the
bulky rhodium intercalators at mismatched DNA sites are en-
antiospecific. It is the -isomer of Rhchrysi that binds and
selectively cleaves a neighboring base pair mismatch, and it is the
-isomer that shows the biological effect preferentially inMMR-
deficient cells. There is therefore a clear correlation if not an
established causality between DNA mismatch targeting by the
rhodium complexes and the observed inhibition of cellular
proliferation in MMR-deficient cells.
These results highlight a class of compounds for possible
application in cancer therapeutics. The work furthermore un-
derscores a cell-selective strategy in chemotherapeutic design by
chemically and site-specifically targeting DNA mismatches.
Materials and Methods
Materials. Rac-Rhchrysi and rac-Rhphzi were synthesized by
using established procedures (15, 18).Rac-Rhchrysi was resolved
into - and -isomers by using potassium antimonyl tartrate as
previously described (23). Salts were exchanged to chloride
before use with Sephadex QAE ion exchange resin. Media and
supplements were purchased from Invitrogen (Carlsbad, CA).
BrdU, antibodies, buffers, and peroxidase substrate were pur-
chased in kit format from Roche Molecular Biochemicals
(Mannheim, Germany). Irradiations were performed with an
Oriel (Darmstadt, Germany) 1,000-W HgXe solar simulator
using a UVBUVC-blocking filter.
Cell Lines, Media, and Culture. The HCT116N and HCT116O cell
lines were obtained from Bert Vogelstein (The Johns Hopkins
University, Baltimore, MD) and were originally derived from
the laboratory of C. R. Boland (University of California at San
Diego, La Jolla, CA) (20). Cells were grown in RPMI medi-
um1640 supplemented with 10% FBS2 mM L-glutamine0.1
mM nonessential amino acids1 mM sodium pyruvate100
units/ml penicillin100 g/ml streptomycin400 g/ml geneti-
cin (G418). Cells were grown in tissue culture f lasks and dishes
(Corning Costar, Acton, MA) at 37°C under 5% CO2 atmo-
sphere. Mouse fibroblasts were obtained as previously re-
ported (24) and established for heterozygous and homozygous
littermates and used at passages 5 and 6. Cells were grown in
DMEM with media as for HCT116 cells.
Cell Proliferation Assays.Cell proliferation wasmeasured using the
BrdU incorporation assay (25). Cells were plated in 96-well
plates at 2,000 cells per well and grown for 24 h. At this point,
variable concentrations of rhodium complexes were added. The
cell cultures were then allowed to grow for 6–96 h as indicated.
Cells were then either irradiated or not followed by the addition
of BrdU. Irradiations of cells were performed by using a solar
simulator adapted for irradiation from the bottom of the well
plates. The cells were grown for an additional 24 h. The BrdU
incorporation was quantified by antibody assay with established
procedures (24, 25). For the experiments with mouse fibroblasts,
cells were plated and after 24 h Rhphzi was added; 12 h later
BrdU was added, and the assays were carried out as established.
Photocleavage of Mismatched DNA with Rhodium Isomers. Photo-
cleavage experiments were conducted on the 436-mer PCR
product as previously described in detail (19) but using 500 nM
of the purified isomers, - or -Rhchrysi.
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